YuceNeo

YuceNeo is a clinical-stage biotechnology company focused on the development of personalized cancer immunotherapies, operating as the therapeutic arm of YuceBio. The company utilizes its proprietary True-Neo platform, which integrates genomic big data and deep learning algorithms to identify and prioritize tumor-specific neoantigens. This technology powers a diverse pipeline of personalized treatments, including peptide-based vaccines, mRNA vaccines, and adoptive cell therapies such as TILs. YuceNeo's lead candidate, YC-NEO-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors. By combining advanced bioinformatics with innovative delivery systems, the company aims to deliver precise, effective, and individualized treatments for cancer patients.